---
title: "Iovance publishes corporate presentation on TIL cell therapy platform, Amtagvi launch and pipeline updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291327737.md"
description: "Iovance Biotherapeutics released a corporate presentation outlining FY2026 revenue guidance of $350M-$370M, driven by ~45% YoY growth. Q2 2026 revenue is guided at $86M-$88M, with cash reserves at $319M. The company highlighted Amtagvi's strong performance, including a 31.4% ORR and real-world data showing 44% ORR. Pipeline updates focus on lifileucel expansion in melanoma and NSCLC, with potential launches in late 2027."
datetime: "2026-06-30T20:01:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291327737.md)
  - [en](https://longbridge.com/en/news/291327737.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291327737.md)
generator: "portal-rs"
---

# Iovance publishes corporate presentation on TIL cell therapy platform, Amtagvi launch and pipeline updates

-   Iovance outlined FY 2026 revenue guidance of $350 million-$370 million, citing about 45% year-over-year quarterly revenue growth. \* Q2 2026 revenue guidance set at $86 million-$88 million; cash reported at about $319 million as of March 31, 2026. \* Amtagvi performance highlighted with 31.4% ORR, 36.5-month median duration of response, 19.7% five-year overall survival, 13.9-month median OS. \* Real-world Amtagvi data showed 44% ORR overall; 52% ORR in patients with two or fewer prior therapy lines. \* Pipeline focus on lifileucel expansion, including TILVANCE-301 in frontline melanoma, IOV-LUN-202 in post-anti-PD-1 NSCLC with potential 2H27 launch. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)

## Related News & Research

- [Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating](https://longbridge.com/en/news/296875833.md)
- [Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News](https://longbridge.com/en/news/296654527.md)
- [Biovica says DiviTum TKa study in metastatic melanoma is published in Clinical Cancer Research](https://longbridge.com/en/news/296871354.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [Lytix says FDA clears Phase III trial plan for ruxotemitide plus pembrolizumab in high-risk melanoma](https://longbridge.com/en/news/297124839.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**